Abstract

APARICIO-HERNANDEZ, R; GARCIA-LUQUE, A; SANCHEZ-DE-CASTRO, M  and  GARCIA-CEREZUELA, M. Positive assessment of drugs: April, May and June 2020. Sanid. Mil. [online]. 2020, vol.76, n.3, pp.177-182.  Epub Mar 08, 2021. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712020000300007.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in April, May and June 2020, and considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Keywords : Alpelisib (Piqray®); Bulevirtida (Hepcludex®); Elexacaftor/Tezacaftor/Ivacaftor (Kaftrio®); Entrectinib (Rozlytrek®); Glasdegib (Daurismo®); Imlifidasa (Idefirix®); Indacaterol/Glicopirronio/Furoato de mometasona(Enerzair Breezhaler® y Zimbus Breezhaler®); Lefamulina (Xenleta®); Luspatercept (Reblozyl®); Remdesivir (Veklury®); Vacuna frente al Ébola (MVA-BNFilo multivalente, recombinante, noreplicativo) (Mvabea®); Vacuna frente al Ébola (Vacuna monovalente recombinante incapaz de replicar con vector ad26 que codifica la longitud completa de glicoproteína (gp) de ébolavirus zaire) (Zabdeno®).

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )